Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12656054 | 0.90 | KMT2A (0.63) | KMT2AGAAL3MBTL1MAPTPKM | |
| SCHEMBL8220120 | 0.79 | GAA (0.56) | KMT2AGAAL3MBTL1MAPTPKM | |
| SCHEMBL265611 | 0.79 | PKM (0.61) | KMT2AGAAPKMMEN1ALDH1A1 | |
| SCHEMBL6559970 | 0.79 | KMT2A (0.56) | KMT2APKMAKR1C3MEN1USP2 | |
| SCHEMBL13271173 | 0.78 | USP2 (0.62) | KMT2AGAAL3MBTL1MAPTPKM | |
| SCHEMBL3633792 | 0.77 | USP2 (0.71) | KMT2AGAAL3MBTL1MAPTPKM | |
| SCHEMBL15231766 | 0.76 | MAPT (0.65) | KMT2AGAAL3MBTL1MAPTPKM | |
| SCHEMBL3637211 | 0.75 | ALDH1A1 (0.55) | KMT2AGAAL3MBTL1MAPTEPHX2 | |
| SCHEMBL5338240 | 0.74 | POLB (0.67) | KMT2AGAAL3MBTL1PKMPKLR | |
| Hydrochloric Acid SCHEMBL3246796 | 0.74 | MAPT (0.63) | KMT2AGAAL3MBTL1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008341-B2 | Central nervous system disorders; autoimmune diseases; anticancer agents; cardiovascular disorders; antiischemic agents; antiepileptic agents ; Alzheimer's disease; Huntington's disease; Parkinson's disease; spinal cord injuries; antiarthritic agents; transplant rejection; sepsis; brain disorders | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-1320526-B1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | MERCK SERONO SA (CH) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255222-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-10-16 | — | — | US | disclosed |
| US-7417058-B2 | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | LABORATOIRES SERONO S.A. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-20040053917-A1 | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | MERCK SERONO SA (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1320526-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | Applied Research Systems ARS Holding N.V. (AN) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002026711-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053917-A1 | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | MAPK3, CBR3, MAPK1 | KMT2A 3518/4885GAA 3624/4885L3MBTL1 4586/4885 |
| US-20080255222-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | MAP3K5, MAP3K2, MAP3K21 | KMT2A 2317/4885GAA 2453/4885L3MBTL1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.